{
  "pmcid": "11051669",
  "sha256": "438719144e02f396f032fe6981f6ccecfda2c19363b557a5489d853a7d5f6007",
  "timestamp_utc": "2025-11-09T23:11:48.534815+00:00",
  "model_used": "gpt-4o",
  "readability": {
    "flesch_kincaid": 13.204063492063494,
    "reading_ease": 30.31871428571432,
    "word_count": 252
  },
  "consort_scores": {
    "rubric_version": "v3.0-2025-10-14",
    "items": {
      "Title": {
        "score": 1,
        "evidence": "Randomised Controlled Trial of Sugammadex Dosing in Morbidly Obese Patients"
      },
      "Trial_Design": {
        "score": 1,
        "evidence": "Eight randomised controlled trials (RCTs) involving 645 participants were included."
      },
      "Participants": {
        "score": 2,
        "evidence": "Participants were MO patients undergoing bariatric surgery."
      },
      "Intervention": {
        "score": 2,
        "evidence": "The intervention was sugammadex dosing based on different weight scalars: total body weight (TBW), ideal body weight (IBW), 20% corrected body weight (CBW), and 40% CBW."
      },
      "Objective": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Method_Outcome": {
        "score": 2,
        "evidence": "The primary outcome was recovery time from moderate or deep NMB, measured by the time to a Train of Four (TOF) ratio of 0.9."
      },
      "Randomisation_Allocation": {
        "score": 0,
        "evidence": "Randomisation methods and allocation concealment varied across studies"
      },
      "Blinding": {
        "score": 0,
        "evidence": "blinding was not consistently reported"
      },
      "Number_Randomised": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Number_Analysed": {
        "score": 1,
        "evidence": "The analysis was conducted using an intention-to-treat approach"
      },
      "Result_Outcome": {
        "score": 2,
        "evidence": "A dose of 2 mg/kg of sugammadex based on 40% CBW and a 4 mg/kg dose based on 40% CBW provided reliable and timely reversal of moderate and deep NMB, respectively."
      },
      "Harms": {
        "score": 1,
        "evidence": "No significant adverse events were reported."
      },
      "Trial_Registration": {
        "score": 0,
        "evidence": "no trial registration number was provided"
      },
      "Funding": {
        "score": 1,
        "evidence": "The study was funded by institutional sources"
      }
    },
    "total_score": 13,
    "max_score": 25
  }
}